A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
PMID: 39250708
Medicaid Coverage Continuity is Associated with Lymphoma Stage among Children and Adolescents/Young Adults.
Medicaid Coverage Continuity is Associated with Lymphoma Stage among Children and Adolescents/Young Adults. Blood Adv. 2024 Nov 12.
PMID: 39531060
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2024 Nov 07.
PMID: 39506897
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305.
PMID: 39110987
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia. Innovation (Camb). 2024 Nov 04; 5(6):100719.
PMID: 39529956
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2024 Oct 17; JCO2400321.
PMID: 39418622
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2024 Oct 07.
PMID: 39374521
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
PMID: 39367245
Abatement of the Survival Cliff in Older Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in the United States.
Abatement of the Survival Cliff in Older Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma in the United States. J Adolesc Young Adult Oncol. 2024 Sep 25.
PMID: 39321033